Review



gluc positive control clone  (Genecopoeia)


Bioz Verified Symbol Genecopoeia is a verified supplier
Bioz Manufacturer Symbol Genecopoeia manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96

    Structured Review

    Genecopoeia gluc positive control clone
    Gluc Positive Control Clone, supplied by Genecopoeia, used in various techniques. Bioz Stars score: 96/100, based on 1460 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/positive+control/GLuc+positive+control+clone/custom%40gapdh-pg02%4042208106
    Average 96 stars, based on 1460 article reviews
    gluc positive control clone - by Bioz Stars, 2026-10
    96/100 stars

    Images

    Related Articles

    other:

    Article Title: Structurally related phage helicases trigger type III-A3 retron-mediated anti-phage defense across diverse tailed phage families
    Article Snippet: Two microliters of the lysed culture were used as a template for PCR reactions with primers containing adapters for Illumina sequencing preparation.

    Clone Assay:

    Article Title: PKD1 5'UTR variants are a rare cause of disease in ADPKD and suggest a new focus for therapeutic development.
    Article Snippet: .. The 5′UTR variants were cloned directly upstream of Gaussia luciferase (GLuc) in the modified pEZX-GA02 plasmid (Genecopoeia; sequence can be supplied on request) and sequenced. ..

    Luciferase:

    Article Title: PKD1 5'UTR variants are a rare cause of disease in ADPKD and suggest a new focus for therapeutic development.
    Article Snippet: .. The 5′UTR variants were cloned directly upstream of Gaussia luciferase (GLuc) in the modified pEZX-GA02 plasmid (Genecopoeia; sequence can be supplied on request) and sequenced. ..

    Article Title: Vitamin B 2 Production by Vaginal Lactobacilli Promotes Symbiosis
    Article Snippet: Succesfull integrants were selected using puromycin (Gibco, 1 μg/mL) for a total of 9 days, while refreshing the medium every 3 days. .. The supernatant was subsequently examined for Gaussia Luciferase (GLuc) activity using the Secrete-PairTM Gaussia Luciferase Assay Kit (GeneCopoiea TM ). ..

    Article Title: Clinicopathological characteristics and cyclosporine-responsive proteinuria in nail-patella syndrome with a novel LMX1B mutation.
    Article Snippet: Background Nephropathy in nail-patella syndrome (NPS) has limited therapeutic options.. Progressive nephrotic-range proteinuria often persists despite maximal renin–angiotensin–aldosterone system inhibitor (RAASi) therapy.. Calcineurin inhibitors such as cyclosporine A (CsA) are unexplored in NPS.

    Article Title: Glycogen engineering improves the starvation resistance of mesenchymal stem cells and their therapeutic efficacy in pulmonary fibrosis
    Article Snippet: Then, 400 μL PBS and twenty 1-mm beads (Servicebio, G0201) were added to the centrifuge tube with lungs for processing with a KZ-III high-speed homogenizer (Servicebio) at 60 Hz for 30 s, six times. .. The homogenate was centrifuged (10,000× g , 5 min), and the activity of Gaussia luciferase in the suspension was detected using a commercial kit (GeneCopoeia, LF061). ..

    Modification:

    Article Title: PKD1 5'UTR variants are a rare cause of disease in ADPKD and suggest a new focus for therapeutic development.
    Article Snippet: .. The 5′UTR variants were cloned directly upstream of Gaussia luciferase (GLuc) in the modified pEZX-GA02 plasmid (Genecopoeia; sequence can be supplied on request) and sequenced. ..

    Plasmid Preparation:

    Article Title: PKD1 5'UTR variants are a rare cause of disease in ADPKD and suggest a new focus for therapeutic development.
    Article Snippet: .. The 5′UTR variants were cloned directly upstream of Gaussia luciferase (GLuc) in the modified pEZX-GA02 plasmid (Genecopoeia; sequence can be supplied on request) and sequenced. ..

    Sequencing:

    Article Title: PKD1 5'UTR variants are a rare cause of disease in ADPKD and suggest a new focus for therapeutic development.
    Article Snippet: .. The 5′UTR variants were cloned directly upstream of Gaussia luciferase (GLuc) in the modified pEZX-GA02 plasmid (Genecopoeia; sequence can be supplied on request) and sequenced. ..

    Activity Assay:

    Article Title: Vitamin B 2 Production by Vaginal Lactobacilli Promotes Symbiosis
    Article Snippet: Succesfull integrants were selected using puromycin (Gibco, 1 μg/mL) for a total of 9 days, while refreshing the medium every 3 days. .. The supernatant was subsequently examined for Gaussia Luciferase (GLuc) activity using the Secrete-PairTM Gaussia Luciferase Assay Kit (GeneCopoiea TM ). ..

    Article Title: Clinicopathological characteristics and cyclosporine-responsive proteinuria in nail-patella syndrome with a novel LMX1B mutation.
    Article Snippet: Background Nephropathy in nail-patella syndrome (NPS) has limited therapeutic options.. Progressive nephrotic-range proteinuria often persists despite maximal renin–angiotensin–aldosterone system inhibitor (RAASi) therapy.. Calcineurin inhibitors such as cyclosporine A (CsA) are unexplored in NPS.

    Article Title: Glycogen engineering improves the starvation resistance of mesenchymal stem cells and their therapeutic efficacy in pulmonary fibrosis
    Article Snippet: Then, 400 μL PBS and twenty 1-mm beads (Servicebio, G0201) were added to the centrifuge tube with lungs for processing with a KZ-III high-speed homogenizer (Servicebio) at 60 Hz for 30 s, six times. .. The homogenate was centrifuged (10,000× g , 5 min), and the activity of Gaussia luciferase in the suspension was detected using a commercial kit (GeneCopoeia, LF061). ..

    Incubation:

    Article Title: Clinicopathological characteristics and cyclosporine-responsive proteinuria in nail-patella syndrome with a novel LMX1B mutation.
    Article Snippet: Background Nephropathy in nail-patella syndrome (NPS) has limited therapeutic options.. Progressive nephrotic-range proteinuria often persists despite maximal renin–angiotensin–aldosterone system inhibitor (RAASi) therapy.. Calcineurin inhibitors such as cyclosporine A (CsA) are unexplored in NPS.

    Cell Culture:

    Article Title: Clinicopathological characteristics and cyclosporine-responsive proteinuria in nail-patella syndrome with a novel LMX1B mutation.
    Article Snippet: Background Nephropathy in nail-patella syndrome (NPS) has limited therapeutic options.. Progressive nephrotic-range proteinuria often persists despite maximal renin–angiotensin–aldosterone system inhibitor (RAASi) therapy.. Calcineurin inhibitors such as cyclosporine A (CsA) are unexplored in NPS.

    Suspension:

    Article Title: Glycogen engineering improves the starvation resistance of mesenchymal stem cells and their therapeutic efficacy in pulmonary fibrosis
    Article Snippet: Then, 400 μL PBS and twenty 1-mm beads (Servicebio, G0201) were added to the centrifuge tube with lungs for processing with a KZ-III high-speed homogenizer (Servicebio) at 60 Hz for 30 s, six times. .. The homogenate was centrifuged (10,000× g , 5 min), and the activity of Gaussia luciferase in the suspension was detected using a commercial kit (GeneCopoeia, LF061). ..



    Similar Products

    96
    Genecopoeia gluc positive control clone
    Gluc Positive Control Clone, supplied by Genecopoeia, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/positive+control/GLuc+positive+control+clone/custom%40gapdh-pg02%4042208106
    Average 96 stars, based on 1 article reviews
    gluc positive control clone - by Bioz Stars, 2026-10
    96/100 stars
      Buy from Supplier

    96
    ATCC positive control snu449 cell line
    SBT777101 demonstrates minimal antigen-specific activation without impact on normal human cell survival. (A) Representative flow cytometry plots showing surface (top) and intracellular (bottom) binding of SBT777101 scFv-Fc (right) relative to isotype control (left) in <t>SNU449</t> cells. (B) In vitro functional characterization using SNU449 cells ± CV-beads. Left: Mean ± SD CD69 expression (only SBT777101 data shown; no activation observed in UT controls). Data analyzed by two-way ANOVA with Sidak’s multiple comparisons test. Right: Cytotoxicity measured as the number of viable target cells remaining, normalized to no-Treg controls. Data analyzed by one-way ANOVA with Tukey’s multiple comparisons test. (C) Percentage of UT (top) or SBT777101 (bottom) Tregs expressing CD69 after 24-h co-culture with normal human primary cells or CV-beads (positive control). Data represent mean ± SD from three replicates. Independent experiments are separated by dashed vertical lines. Comparisons were made for media alone compared with in the presence of primary cells for each type and analyzed by two-tailed unpaired t -test. (D) Cytotoxicity (mean ± SD) of SBT777101 and UT Tregs against the same primary cell panel, normalized to no-Treg controls. Data analyzed by one-way ANOVA with Tukey’s multiple comparisons test. (E) Fold-change in CD71 expression (mean ± SD; relative to media control) across three donors after 72-h culture with media, CitP − SKNBE2 cells, CitP + SNU449 cells, human brain astrocytes (HBA), or CV-beads. CV beads were prepared in RPMI or AGM media as appropriate. Full lysis controls (B, D) represent target cells treated with Triton X-100. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. All experiments included 3 technical replicates. AGM, astrocyte growth medium; CitP, citrullinated protein; CV, citrullinated vimentin; HMEC, human mammary epithelial cells; NHBE, normal human bronchial epithelial cells; NHDF, normal human dermal fibroblasts; PrEC, prostate epithelial cells; RPTEC, renal proximal tubule epithelial cells; scFv, single-chain variable fragment; UT, untransduced.
    Positive Control Snu449 Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/positive+control/SNU-449/pmc13637847-74-56-60
    Average 96 stars, based on 1 article reviews
    positive control snu449 cell line - by Bioz Stars, 2026-10
    96/100 stars
      Buy from Supplier

    94
    Beyotime tunel assay kit ere
    SBT777101 demonstrates minimal antigen-specific activation without impact on normal human cell survival. (A) Representative flow cytometry plots showing surface (top) and intracellular (bottom) binding of SBT777101 scFv-Fc (right) relative to isotype control (left) in <t>SNU449</t> cells. (B) In vitro functional characterization using SNU449 cells ± CV-beads. Left: Mean ± SD CD69 expression (only SBT777101 data shown; no activation observed in UT controls). Data analyzed by two-way ANOVA with Sidak’s multiple comparisons test. Right: Cytotoxicity measured as the number of viable target cells remaining, normalized to no-Treg controls. Data analyzed by one-way ANOVA with Tukey’s multiple comparisons test. (C) Percentage of UT (top) or SBT777101 (bottom) Tregs expressing CD69 after 24-h co-culture with normal human primary cells or CV-beads (positive control). Data represent mean ± SD from three replicates. Independent experiments are separated by dashed vertical lines. Comparisons were made for media alone compared with in the presence of primary cells for each type and analyzed by two-tailed unpaired t -test. (D) Cytotoxicity (mean ± SD) of SBT777101 and UT Tregs against the same primary cell panel, normalized to no-Treg controls. Data analyzed by one-way ANOVA with Tukey’s multiple comparisons test. (E) Fold-change in CD71 expression (mean ± SD; relative to media control) across three donors after 72-h culture with media, CitP − SKNBE2 cells, CitP + SNU449 cells, human brain astrocytes (HBA), or CV-beads. CV beads were prepared in RPMI or AGM media as appropriate. Full lysis controls (B, D) represent target cells treated with Triton X-100. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. All experiments included 3 technical replicates. AGM, astrocyte growth medium; CitP, citrullinated protein; CV, citrullinated vimentin; HMEC, human mammary epithelial cells; NHBE, normal human bronchial epithelial cells; NHDF, normal human dermal fibroblasts; PrEC, prostate epithelial cells; RPTEC, renal proximal tubule epithelial cells; scFv, single-chain variable fragment; UT, untransduced.
    Tunel Assay Kit Ere, supplied by Beyotime, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/positive+control/Positive+Control+Preparation+Kit+for+TUNEL+Assay/pm42768773-217-19-25
    Average 94 stars, based on 1 article reviews
    tunel assay kit ere - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    94
    MedChemExpress positive control group 316
    SBT777101 demonstrates minimal antigen-specific activation without impact on normal human cell survival. (A) Representative flow cytometry plots showing surface (top) and intracellular (bottom) binding of SBT777101 scFv-Fc (right) relative to isotype control (left) in <t>SNU449</t> cells. (B) In vitro functional characterization using SNU449 cells ± CV-beads. Left: Mean ± SD CD69 expression (only SBT777101 data shown; no activation observed in UT controls). Data analyzed by two-way ANOVA with Sidak’s multiple comparisons test. Right: Cytotoxicity measured as the number of viable target cells remaining, normalized to no-Treg controls. Data analyzed by one-way ANOVA with Tukey’s multiple comparisons test. (C) Percentage of UT (top) or SBT777101 (bottom) Tregs expressing CD69 after 24-h co-culture with normal human primary cells or CV-beads (positive control). Data represent mean ± SD from three replicates. Independent experiments are separated by dashed vertical lines. Comparisons were made for media alone compared with in the presence of primary cells for each type and analyzed by two-tailed unpaired t -test. (D) Cytotoxicity (mean ± SD) of SBT777101 and UT Tregs against the same primary cell panel, normalized to no-Treg controls. Data analyzed by one-way ANOVA with Tukey’s multiple comparisons test. (E) Fold-change in CD71 expression (mean ± SD; relative to media control) across three donors after 72-h culture with media, CitP − SKNBE2 cells, CitP + SNU449 cells, human brain astrocytes (HBA), or CV-beads. CV beads were prepared in RPMI or AGM media as appropriate. Full lysis controls (B, D) represent target cells treated with Triton X-100. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. All experiments included 3 technical replicates. AGM, astrocyte growth medium; CitP, citrullinated protein; CV, citrullinated vimentin; HMEC, human mammary epithelial cells; NHBE, normal human bronchial epithelial cells; NHDF, normal human dermal fibroblasts; PrEC, prostate epithelial cells; RPTEC, renal proximal tubule epithelial cells; scFv, single-chain variable fragment; UT, untransduced.
    Positive Control Group 316, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/positive+control/Sodium+carboxymethyl+cellulose/pm42567486-151-55-60
    Average 94 stars, based on 1 article reviews
    positive control group 316 - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    94
    MedChemExpress control il17a inhibitor
    Clusters of <t>IL17A</t> experimentally validated hits.
    Control Il17a Inhibitor, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/positive+control/LY3509754/bio_rxiv__64898__2026__08__03__742480-847-7-1
    Average 94 stars, based on 1 article reviews
    control il17a inhibitor - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    94
    MedChemExpress control irak4 inhibitor
    Prospective virtual screening campaigns were conducted against four therapeutically relevant targets representing distinct target classes and binding-site architectures. CD73 (nucleotidase), <t>IRAK4</t> (kinase), and Factor XI (FXIa protease) were targeted through orthosteric inhibition, whereas IL-17A, a protein–protein interaction (PPI) target, was targeted through an allosteric binding site. For each target, the experimentally determined hit rate, a representative validated hit, its biochemical potency ( IC 50), and its structural similarity to the closest previously reported inhibitor (ECFP4 Tanimoto coefficient) are shown. The prospective campaigns identified 56 active compounds from 183 tested for CD73, 19 from 127 for IRAK4, 13 from 299 for Factor XI, and 6 from 194 for IL-17A. Across all four targets, representative hits exhibited low structural similarity to known inhibitors (ECFP4 Tanimoto coefficients of 0.22–0.27), demonstrating the ability of the virtual screening workflow to prospectively identify chemically novel scaffolds across both conventional orthosteric targets and more challenging protein–protein interaction targets.
    Control Irak4 Inhibitor, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/positive+control/IRAK4%2C+Human/bio_rxiv__64898__2026__08__03__742480-783-7-1
    Average 94 stars, based on 1 article reviews
    control irak4 inhibitor - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    86
    Agrisera rubisco positive control
    Prospective virtual screening campaigns were conducted against four therapeutically relevant targets representing distinct target classes and binding-site architectures. CD73 (nucleotidase), <t>IRAK4</t> (kinase), and Factor XI (FXIa protease) were targeted through orthosteric inhibition, whereas IL-17A, a protein–protein interaction (PPI) target, was targeted through an allosteric binding site. For each target, the experimentally determined hit rate, a representative validated hit, its biochemical potency ( IC 50), and its structural similarity to the closest previously reported inhibitor (ECFP4 Tanimoto coefficient) are shown. The prospective campaigns identified 56 active compounds from 183 tested for CD73, 19 from 127 for IRAK4, 13 from 299 for Factor XI, and 6 from 194 for IL-17A. Across all four targets, representative hits exhibited low structural similarity to known inhibitors (ECFP4 Tanimoto coefficients of 0.22–0.27), demonstrating the ability of the virtual screening workflow to prospectively identify chemically novel scaffolds across both conventional orthosteric targets and more challenging protein–protein interaction targets.
    Rubisco Positive Control, supplied by Agrisera, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/positive+control/control+positive+rubisco/pm42296348-325-1-5
    Average 86 stars, based on 1 article reviews
    rubisco positive control - by Bioz Stars, 2026-10
    86/100 stars
      Buy from Supplier

    86
    Kemin Industries salinomycin 60 ppm positive control group 2 eimeria tenella infection
    Prospective virtual screening campaigns were conducted against four therapeutically relevant targets representing distinct target classes and binding-site architectures. CD73 (nucleotidase), <t>IRAK4</t> (kinase), and Factor XI (FXIa protease) were targeted through orthosteric inhibition, whereas IL-17A, a protein–protein interaction (PPI) target, was targeted through an allosteric binding site. For each target, the experimentally determined hit rate, a representative validated hit, its biochemical potency ( IC 50), and its structural similarity to the closest previously reported inhibitor (ECFP4 Tanimoto coefficient) are shown. The prospective campaigns identified 56 active compounds from 183 tested for CD73, 19 from 127 for IRAK4, 13 from 299 for Factor XI, and 6 from 194 for IL-17A. Across all four targets, representative hits exhibited low structural similarity to known inhibitors (ECFP4 Tanimoto coefficients of 0.22–0.27), demonstrating the ability of the virtual screening workflow to prospectively identify chemically novel scaffolds across both conventional orthosteric targets and more challenging protein–protein interaction targets.
    Salinomycin 60 Ppm Positive Control Group 2 Eimeria Tenella Infection, supplied by Kemin Industries, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/positive+control/2+60+control+eimeria+group+infection+positive+ppm+salinomycin+tenella/us12648919-143-31-46
    Average 86 stars, based on 1 article reviews
    salinomycin 60 ppm positive control group 2 eimeria tenella infection - by Bioz Stars, 2026-10
    86/100 stars
      Buy from Supplier

    86
    Shanghai Yuanye Biochemicals positive control group
    Prospective virtual screening campaigns were conducted against four therapeutically relevant targets representing distinct target classes and binding-site architectures. CD73 (nucleotidase), <t>IRAK4</t> (kinase), and Factor XI (FXIa protease) were targeted through orthosteric inhibition, whereas IL-17A, a protein–protein interaction (PPI) target, was targeted through an allosteric binding site. For each target, the experimentally determined hit rate, a representative validated hit, its biochemical potency ( IC 50), and its structural similarity to the closest previously reported inhibitor (ECFP4 Tanimoto coefficient) are shown. The prospective campaigns identified 56 active compounds from 183 tested for CD73, 19 from 127 for IRAK4, 13 from 299 for Factor XI, and 6 from 194 for IL-17A. Across all four targets, representative hits exhibited low structural similarity to known inhibitors (ECFP4 Tanimoto coefficients of 0.22–0.27), demonstrating the ability of the virtual screening workflow to prospectively identify chemically novel scaffolds across both conventional orthosteric targets and more challenging protein–protein interaction targets.
    Positive Control Group, supplied by Shanghai Yuanye Biochemicals, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/positive+control/control+group+positive/10__1111_slash_jocd__70969-121-55-63
    Average 86 stars, based on 1 article reviews
    positive control group - by Bioz Stars, 2026-10
    86/100 stars
      Buy from Supplier

    99
    Zymo Research positive controls
    Prospective virtual screening campaigns were conducted against four therapeutically relevant targets representing distinct target classes and binding-site architectures. CD73 (nucleotidase), <t>IRAK4</t> (kinase), and Factor XI (FXIa protease) were targeted through orthosteric inhibition, whereas IL-17A, a protein–protein interaction (PPI) target, was targeted through an allosteric binding site. For each target, the experimentally determined hit rate, a representative validated hit, its biochemical potency ( IC 50), and its structural similarity to the closest previously reported inhibitor (ECFP4 Tanimoto coefficient) are shown. The prospective campaigns identified 56 active compounds from 183 tested for CD73, 19 from 127 for IRAK4, 13 from 299 for Factor XI, and 6 from 194 for IL-17A. Across all four targets, representative hits exhibited low structural similarity to known inhibitors (ECFP4 Tanimoto coefficients of 0.22–0.27), demonstrating the ability of the virtual screening workflow to prospectively identify chemically novel scaffolds across both conventional orthosteric targets and more challenging protein–protein interaction targets.
    Positive Controls, supplied by Zymo Research, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/positive+control/ZymoBIOMICS+Microbial+Community+Standard/pmc12954305-58-4-10
    Average 99 stars, based on 1 article reviews
    positive controls - by Bioz Stars, 2026-10
    99/100 stars
      Buy from Supplier

    Image Search Results


    SBT777101 demonstrates minimal antigen-specific activation without impact on normal human cell survival. (A) Representative flow cytometry plots showing surface (top) and intracellular (bottom) binding of SBT777101 scFv-Fc (right) relative to isotype control (left) in SNU449 cells. (B) In vitro functional characterization using SNU449 cells ± CV-beads. Left: Mean ± SD CD69 expression (only SBT777101 data shown; no activation observed in UT controls). Data analyzed by two-way ANOVA with Sidak’s multiple comparisons test. Right: Cytotoxicity measured as the number of viable target cells remaining, normalized to no-Treg controls. Data analyzed by one-way ANOVA with Tukey’s multiple comparisons test. (C) Percentage of UT (top) or SBT777101 (bottom) Tregs expressing CD69 after 24-h co-culture with normal human primary cells or CV-beads (positive control). Data represent mean ± SD from three replicates. Independent experiments are separated by dashed vertical lines. Comparisons were made for media alone compared with in the presence of primary cells for each type and analyzed by two-tailed unpaired t -test. (D) Cytotoxicity (mean ± SD) of SBT777101 and UT Tregs against the same primary cell panel, normalized to no-Treg controls. Data analyzed by one-way ANOVA with Tukey’s multiple comparisons test. (E) Fold-change in CD71 expression (mean ± SD; relative to media control) across three donors after 72-h culture with media, CitP − SKNBE2 cells, CitP + SNU449 cells, human brain astrocytes (HBA), or CV-beads. CV beads were prepared in RPMI or AGM media as appropriate. Full lysis controls (B, D) represent target cells treated with Triton X-100. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. All experiments included 3 technical replicates. AGM, astrocyte growth medium; CitP, citrullinated protein; CV, citrullinated vimentin; HMEC, human mammary epithelial cells; NHBE, normal human bronchial epithelial cells; NHDF, normal human dermal fibroblasts; PrEC, prostate epithelial cells; RPTEC, renal proximal tubule epithelial cells; scFv, single-chain variable fragment; UT, untransduced.

    Journal: Toxicological Sciences

    Article Title: Nonclinical safety assessment of SBT777101, a CAR-engineered regulatory T cell therapy for autoimmune diseases

    doi: 10.1093/toxsci/kfag125

    Figure Lengend Snippet: SBT777101 demonstrates minimal antigen-specific activation without impact on normal human cell survival. (A) Representative flow cytometry plots showing surface (top) and intracellular (bottom) binding of SBT777101 scFv-Fc (right) relative to isotype control (left) in SNU449 cells. (B) In vitro functional characterization using SNU449 cells ± CV-beads. Left: Mean ± SD CD69 expression (only SBT777101 data shown; no activation observed in UT controls). Data analyzed by two-way ANOVA with Sidak’s multiple comparisons test. Right: Cytotoxicity measured as the number of viable target cells remaining, normalized to no-Treg controls. Data analyzed by one-way ANOVA with Tukey’s multiple comparisons test. (C) Percentage of UT (top) or SBT777101 (bottom) Tregs expressing CD69 after 24-h co-culture with normal human primary cells or CV-beads (positive control). Data represent mean ± SD from three replicates. Independent experiments are separated by dashed vertical lines. Comparisons were made for media alone compared with in the presence of primary cells for each type and analyzed by two-tailed unpaired t -test. (D) Cytotoxicity (mean ± SD) of SBT777101 and UT Tregs against the same primary cell panel, normalized to no-Treg controls. Data analyzed by one-way ANOVA with Tukey’s multiple comparisons test. (E) Fold-change in CD71 expression (mean ± SD; relative to media control) across three donors after 72-h culture with media, CitP − SKNBE2 cells, CitP + SNU449 cells, human brain astrocytes (HBA), or CV-beads. CV beads were prepared in RPMI or AGM media as appropriate. Full lysis controls (B, D) represent target cells treated with Triton X-100. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. All experiments included 3 technical replicates. AGM, astrocyte growth medium; CitP, citrullinated protein; CV, citrullinated vimentin; HMEC, human mammary epithelial cells; NHBE, normal human bronchial epithelial cells; NHDF, normal human dermal fibroblasts; PrEC, prostate epithelial cells; RPTEC, renal proximal tubule epithelial cells; scFv, single-chain variable fragment; UT, untransduced.

    Article Snippet: Primary human cells (mammary epithelial cells [HMEC; Lonza Cat#CC-2551], normal bronchial epithelial cells [NHBE; Lonza Cat#CC2451], renal proximal tubule epithelial cells [RPTEC; Lonza Cat#CC2553], prostate epithelial cells [PrEC; Lonza Cat#CC2555], hepatocytes [Lonza Cat#HUCPG], brain astrocytes [HBA; Neuromics Cat#HMP202], iPSC-derived myocytes [Tempo Bioscience Cat#1014], iPSC-derived cortical neurons [Tempo Bioscience Cat#201], and monocyte-derived macrophages [internally derived]) and the positive-control SNU449 cell line (ATCC Cat#CRL-2234) were assessed for binding of the SBT777101 scFv by flow cytometry.

    Techniques: Activation Assay, Flow Cytometry, Binding Assay, Control, In Vitro, Functional Assay, Expressing, Co-culture Assay, Positive Control, Two Tailed Test, Lysis

    Clusters of IL17A experimentally validated hits.

    Journal: bioRxiv

    Article Title: Overcoming the accuracy–generalization tradeoff in docking and scoring for prospective virtual screening

    doi: 10.64898/2026.08.03.742480

    Figure Lengend Snippet: Clusters of IL17A experimentally validated hits.

    Article Snippet: LY3509754 (MedChemExpress, HY-139206) was used as a positive-control IL17A inhibitor.

    Techniques:

    Prospective virtual screening campaigns were conducted against four therapeutically relevant targets representing distinct target classes and binding-site architectures. CD73 (nucleotidase), IRAK4 (kinase), and Factor XI (FXIa protease) were targeted through orthosteric inhibition, whereas IL-17A, a protein–protein interaction (PPI) target, was targeted through an allosteric binding site. For each target, the experimentally determined hit rate, a representative validated hit, its biochemical potency ( IC 50), and its structural similarity to the closest previously reported inhibitor (ECFP4 Tanimoto coefficient) are shown. The prospective campaigns identified 56 active compounds from 183 tested for CD73, 19 from 127 for IRAK4, 13 from 299 for Factor XI, and 6 from 194 for IL-17A. Across all four targets, representative hits exhibited low structural similarity to known inhibitors (ECFP4 Tanimoto coefficients of 0.22–0.27), demonstrating the ability of the virtual screening workflow to prospectively identify chemically novel scaffolds across both conventional orthosteric targets and more challenging protein–protein interaction targets.

    Journal: bioRxiv

    Article Title: Overcoming the accuracy–generalization tradeoff in docking and scoring for prospective virtual screening

    doi: 10.64898/2026.08.03.742480

    Figure Lengend Snippet: Prospective virtual screening campaigns were conducted against four therapeutically relevant targets representing distinct target classes and binding-site architectures. CD73 (nucleotidase), IRAK4 (kinase), and Factor XI (FXIa protease) were targeted through orthosteric inhibition, whereas IL-17A, a protein–protein interaction (PPI) target, was targeted through an allosteric binding site. For each target, the experimentally determined hit rate, a representative validated hit, its biochemical potency ( IC 50), and its structural similarity to the closest previously reported inhibitor (ECFP4 Tanimoto coefficient) are shown. The prospective campaigns identified 56 active compounds from 183 tested for CD73, 19 from 127 for IRAK4, 13 from 299 for Factor XI, and 6 from 194 for IL-17A. Across all four targets, representative hits exhibited low structural similarity to known inhibitors (ECFP4 Tanimoto coefficients of 0.22–0.27), demonstrating the ability of the virtual screening workflow to prospectively identify chemically novel scaffolds across both conventional orthosteric targets and more challenging protein–protein interaction targets.

    Article Snippet: Zimlovisertib (MedChemExpress, HY-19836) was used as a positive-control IRAK4 inhibitor.

    Techniques: Binding Assay, Inhibition

    (a) Prospective virtual screening workflow. Approximately 80 billion compounds from Enamine REAL Space were computationally screened and progressively prioritized to 153 compounds for procurement, of which 127 were experimentally evaluated. The number of compounds remaining after each filtering stage and the corresponding biochemical and cellular hit rates are shown. (b) Characterization of validated hits. Top, single-concentration biochemical inhibition measured at 100 and 10 μM . Middle, molecular weight (MW) and topological polar surface area (TPSA) distributions of validated hits. Bottom left, UMAP projection of ECFP4 fingerprints comparing validated hits (orange) with previously reported IRAK4 inhibitors (blue). Bottom right, distribution of ECFP4 Tanimoto similarity between validated hits and the closest known IRAK4 inhibitor, illustrating the chemical novelty of the identified compounds. (c) Representative validated IRAK4 inhibitors. Chemical structures, biochemical and cellular IC 50 values, physicochemical properties, and representative dose-response curves for two non-nucleotide inhibitors.

    Journal: bioRxiv

    Article Title: Overcoming the accuracy–generalization tradeoff in docking and scoring for prospective virtual screening

    doi: 10.64898/2026.08.03.742480

    Figure Lengend Snippet: (a) Prospective virtual screening workflow. Approximately 80 billion compounds from Enamine REAL Space were computationally screened and progressively prioritized to 153 compounds for procurement, of which 127 were experimentally evaluated. The number of compounds remaining after each filtering stage and the corresponding biochemical and cellular hit rates are shown. (b) Characterization of validated hits. Top, single-concentration biochemical inhibition measured at 100 and 10 μM . Middle, molecular weight (MW) and topological polar surface area (TPSA) distributions of validated hits. Bottom left, UMAP projection of ECFP4 fingerprints comparing validated hits (orange) with previously reported IRAK4 inhibitors (blue). Bottom right, distribution of ECFP4 Tanimoto similarity between validated hits and the closest known IRAK4 inhibitor, illustrating the chemical novelty of the identified compounds. (c) Representative validated IRAK4 inhibitors. Chemical structures, biochemical and cellular IC 50 values, physicochemical properties, and representative dose-response curves for two non-nucleotide inhibitors.

    Article Snippet: Zimlovisertib (MedChemExpress, HY-19836) was used as a positive-control IRAK4 inhibitor.

    Techniques: Concentration Assay, Inhibition, Molecular Weight